

Neuronetics, Inc. Supplemental Financial and Operating Information

For the period ended September 30, 2021

Revenue (\$ thousands)	2019				2020				2021	2021	2021	2019	2020
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	FY	FY
NeuroStar Capital (1)	\$2,939	\$4,034	\$4,264	\$4,959	\$2,410	\$2,224	\$2,438	\$3,446	\$1,589	\$2,441	\$2,277	\$16,196	\$10,518
YoY Change	54%	23%	24%	14%	-18%	-45%	-43%	-31%	-34%	10%	-7%	25%	-35%
NeuroStar Operating Lease (2)	\$182	\$187	\$184	\$177	\$155	\$114	\$88	\$79	\$108	\$55	\$30	\$730	\$437
YoY Change	-29%	3%	-31%	-24%	-15%	-39%	-52%	-55%	-31%	-51%	-66%	-22%	-40%
Other (3)	\$229	\$407	\$167	\$278	\$29	\$0	\$15	\$96	\$58	\$81	\$305	\$1,081	\$140
YoY Change	11%	239%	-21%	50%	-87%	-100%	-91%	-66%	100%	100%	1933%	50%	-87%
Total U.S. NeuroStar Advanced Therapy System Revenues	\$3,350	\$4,628	\$4,616	\$5,413	\$2,594	\$2,338	\$2,541	\$3,620	\$1,755	\$2,577	\$2,612	\$18,007	\$11,094
YoY Change	41%	30%	18%	14%	-23%	-49%	-45%	-33%	-32%	10%	3%	23%	-38%
Total U.S. Treatment Sessions Revenues	\$8,778	\$10,847	\$10,252	\$11,243	\$8,193	\$6,547	\$9,083	\$11,029	\$9,629	\$10,801	\$10,259	\$41,120	\$34,852
YoY Change	21%	22%	11%	13%	-7%	-40%	-11%	-2%	18%	65%	13%	17%	-15%
Total U.S. Other Revenues	\$418	\$415	\$426	\$374	\$390	\$382	\$404	\$397	\$419	\$431	\$409	\$1,633	\$1,574
YoY Change	16%	1%	9%	-12%	-7%	-8%	-5%	6%	7%	13%	1%	3%	-4%
Total U.S. Revenues	\$12,546	\$15,890	\$15,294	\$17,030	\$11,177	\$9,267	\$12,029	\$15,046	\$11,802	\$13,809	\$13,280	\$60,760	\$47,519
YoY Change	26%	23%	13%	13%	-11%	-42%	-21%	-12%	6%	49%	10%	18%	-22%
Total International Revenues	\$182	\$682	\$706	\$326	\$299	\$474	\$419	\$533	\$486	\$394	\$519	\$1,896	\$1,725
YoY Change	1%	93%	222%	-40%	64%	-31%	-41%	64%	63%	-17%	24%	46%	-9%
Total Revenues	\$12,728	\$16,572	\$16,000	\$17,356	\$11,476	\$9,741	\$12,448	\$15,579	\$12,288	\$14,203	\$13,799	\$62,656	\$49,244
YoY Change	25%	25%	16%	11%	-10%	-41%	-22%	-10%	7%	46%	11%	19%	-21%
U.S. Operating and Financial Metrics	2019				2020				2021			2019	2020
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	FY	FY
Total NeuroStar Systems Sold (4)	43	61	68	78	38	35	39	54	23	36	40	250	166
YoY Change	79%	42%	45%	28%	-12%	-43%	-43%	-31%	-39%	3%	3%	43%	-34%
Average Revenue Per Active Site (\$) (5)	\$12,415	\$14,718	\$13,177	\$13,497	\$9,418	\$7,406	\$10,218	\$12,133	\$10,512	\$12,001	\$11,163	\$58,162	\$40,060
YoY Change	NA	29%	17%	17%	-24%	-50%	-22%	-10%	12%	62%	9%	12%	-31%

(1) = Revenue from Capital Sales and Sales Type Leases

(2) = Revenue derived from Operating Lease revenue during the period

(3) = Primarily includes revenue derived from Treatment Coils in US

(4) = Includes all systems sold during the period, both as Capital Sales or Sales-Type-Leases and (7) Operating leases for Q3 2021

(5) = Total U.S. Treatment Session Revenue / Active Sites (End of Prior Period)